Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
Date:8/6/2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended June 30, 2009, on Monday, August 10, 2009, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Monday, August 10, 2009. Also participating on the call will be Stephanie R. Irish, Acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

    The teleconference dial-in numbers are as follows:
    Domestic callers 1-800-599-9829
    International callers 1-617-847-8703
    Participant Passcode 93125446

The conference call will be broadcast simultaneously and archived on the Company's Web site, www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Monday, August 10, beginning at 1:00 PM ET and will be accessible until Monday, August 17, 2009, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 78449791.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
2. Vanda Pharmaceuticals Reports First Quarter 2009 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
7. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
8. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
9. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
10. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
11. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... type 2 diabetes, announced that it has obtained ... (AAV) vector developed in the laboratory of Professor ... University. The company plans to use this vector ... pipeline. "Early research has shown ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
Breaking Biology Technology:
(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
Breaking Biology News(10 mins):